Literature DB >> 29700205

Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer.

Patrick M Cotogno1, Lahiru K Ranasinghe1, Elisa M Ledet1, Brian E Lewis1, Oliver Sartor2.   

Abstract

BACKGROUND: Metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases have a poor prognosis. No large studies have investigated the clinical and biochemical parameters associated with liver metastases in this population.
MATERIALS AND METHODS: Patient data made available via Project Data Sphere were collected from 1,281 men with mCRPC who were enrolled on to three phase III clinical trials for the treatment of their disease. Multiple logistic regression was performed on eight clinical and biochemical baseline variables to test their association with the presence of liver metastases on baseline radiographic imaging. Variables of interest included prior docetaxel exposure, Eastern Cooperative Oncology Group performance status, albumin, alkaline phosphatase, alanine transaminase, aspartate transaminase (AST), hemoglobin (HGB), lactate dehydrogenase (LDH), prostate-specific antigen, and total bilirubin. Final models were compared when treating the variables as either continuous or categorized.
RESULTS: Multiple variable analysis demonstrated that an increasing serum AST or LDH or a decreasing HGB was associated with an increased probability of having documented radiographic liver metastases (p < .0001). The area under the curve for the continuous model was 0.6842 and 0.6890 for the categorical one, with the latter model containing a dichotomized AST and LDH based on the upper limit of normal and tertile ranges of HGB based on the distribution of the outcome.
CONCLUSION: Our analysis demonstrated a significant association between the presence of liver metastases and laboratory levels of AST, LDH, and HGB. These have implications for patient management. More research is needed to validate these biomarkers and prospectively determine their application in the clinical setting. IMPLICATIONS FOR PRACTICE: The purpose of this study was to evaluate biochemical and clinical biomarkers associated with the presence of liver metastases in men diagnosed with metastatic castrate-resistant prostate cancer. The results indicate that quantitative assessments of aspartate transaminase, lactate dehydrogenase, and hemoglobin are significantly associated with an increased probability of having documented radiographic liver metastases. Analysis of these simple variables can alert clinicians to those at high risk for prostate cancer that has spread to the liver, a finding of clear importance for clinical management. © AlphaMed Press 2018.

Entities:  

Keywords:  Aspartate transaminase; Biomarkers; Lactate dehydrogenase; Liver metastases; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29700205      PMCID: PMC6058331          DOI: 10.1634/theoncologist.2017-0564

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  25 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Authors:  Susan Halabi; Chen-Yen Lin; W Kevin Kelly; Karim S Fizazi; Judd W Moul; Ellen B Kaplan; Michael J Morris; Eric J Small
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

3.  Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.

Authors:  Yohann Loriot; Karim Fizazi; Johann S de Bono; David Forer; Mohammad Hirmand; Howard I Scher
Journal:  Cancer       Date:  2016-09-20       Impact factor: 6.860

4.  Clinical characteristics and prognostic factors of prostate cancer with liver metastases.

Authors:  HaiTao Wang; BaoGuo Li; PengYu Zhang; YanHong Yao; JiWu Chang
Journal:  Tumour Biol       Date:  2014-01

5.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Authors:  Ian F Tannock; Karim Fizazi; Sergey Ivanov; Camilla Thellenberg Karlsson; Aude Fléchon; Iwona Skoneczna; Francisco Orlandi; Gwenaelle Gravis; Vsevolod Matveev; Sevil Bavbek; Thierry Gil; Luciano Viana; Osvaldo Arén; Oleg Karyakin; Tony Elliott; Alison Birtle; Emmanuelle Magherini; Laurence Hatteville; Daniel Petrylak; Bertrand Tombal; Mark Rosenthal
Journal:  Lancet Oncol       Date:  2013-06-04       Impact factor: 41.316

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Authors:  Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

8.  Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

Authors:  C Marchal; M Redondo; M Padilla; J Caballero; I Rodrigo; J García; J Quian; D G Boswick
Journal:  Histol Histopathol       Date:  2004-07       Impact factor: 2.303

9.  A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Authors:  K N Chi; T Kheoh; C J Ryan; A Molina; J Bellmunt; N J Vogelzang; D E Rathkopf; K Fizazi; P W Kantoff; J Li; A A Azad; B J Eigl; D Y C Heng; A M Joshua; J S de Bono; H I Scher
Journal:  Ann Oncol       Date:  2015-12-18       Impact factor: 32.976

10.  Visceral disease in castration-resistant prostate cancer.

Authors:  C Pezaro; A Omlin; D Lorente; D Nava Rodrigues; R Ferraldeschi; D Bianchini; D Mukherji; R Riisnaes; A Altavilla; M Crespo; N Tunariu; J de Bono; G Attard
Journal:  Eur Urol       Date:  2013-11-22       Impact factor: 20.096

View more
  5 in total

1.  Incidence of Elevated Aminotransferases With or Without Bilirubin Elevation During Treatment With Immune Checkpoint Inhibitors: A Retrospective Study of Patients From Community Oncology Clinics in the United States.

Authors:  Christopher Kim; Shao Zhu; Hosein Kouros-Mehr; Sophia Khaldoyanidi
Journal:  Cureus       Date:  2022-04-11

2.  Characterization of Kinase Expression Related to Increased Migration of PC-3M Cells Using Global Comparative Phosphoproteome Analysis.

Authors:  Yan Gao; Yun-Sok Ha; Tae Gyun Kwon; Young-Chang Cho; Sangkyu Lee; Jun Nyung Lee
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

Review 3.  Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology.

Authors:  James H Lewis; Sophia K Khaldoyanidi; Carolyn D Britten; Andrew H Wei; Marion Subklewe
Journal:  Am J Clin Oncol       Date:  2022-07-18       Impact factor: 2.787

4.  The homogeneity and heterogeneity of occurrence, characteristics, and prognosis in hepatocellular carcinoma patients with synchronous and metachronous bone metastasis.

Authors:  Yanting Zhang; Yao Xu; Wenjuan Ma; Haixiao Wu; Guijun Xu; Vladimir P Chekhonin; Karl Peltzer; Xin Wang; Guowen Wang; Chao Zhang
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

5.  The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy.

Authors:  Miaomiao Gou; Yong Zhang; Tiee Liu; Tongtong Qu; Haiyan Si; Zhikuan Wang; Huan Yan; Niansong Qian; Guanghai Dai
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.